NASDAQ
HALO

Halozyme Therapeutics Inc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Halozyme Therapeutics Inc Stock Price

Vitals

Today's Low:
$37.47
Today's High:
$39.055
Open Price:
$37.62
52W Low:
$29.85
52W High:
$59.46
Prev. Close:
$37.5
Volume:
901603

Company Statistics

Market Cap.:
$4.95 billion
Book Value:
1.145
Revenue TTM:
$773.65 million
Operating Margin TTM:
42.39%
Gross Profit TTM:
$454.21 million
Profit Margin:
30.21%
Return on Assets TTM:
11.41%
Return on Equity TTM:
105.22%

Company Profile

Halozyme Therapeutics Inc had its IPO on 2004-03-16 under the ticker symbol HALO.

The company operates in the Healthcare sector and Biotechnology industry. Halozyme Therapeutics Inc has a staff strength of 393 employees.

Stock update

Shares of Halozyme Therapeutics Inc opened at $37.62 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $37.47 - $39.06, and closed at $38.92.

This is a +3.79% increase from the previous day's closing price.

A total volume of 901,603 shares were traded at the close of the day’s session.

In the last one week, shares of Halozyme Therapeutics Inc have slipped by -9.11%.

Halozyme Therapeutics Inc's Key Ratios

Halozyme Therapeutics Inc has a market cap of $4.95 billion, indicating a price to book ratio of 81.5815 and a price to sales ratio of 13.2809.

In the last 12-months Halozyme Therapeutics Inc’s revenue was $773.65 million with a gross profit of $454.21 million and an EBITDA of $400.56 million. The EBITDA ratio measures Halozyme Therapeutics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Halozyme Therapeutics Inc’s operating margin was 42.39% while its return on assets stood at 11.41% with a return of equity of 105.22%.

In Q2, Halozyme Therapeutics Inc’s quarterly earnings growth was a positive 250% while revenue growth was a positive 45.1%.

Halozyme Therapeutics Inc’s PE and PEG Ratio

Forward PE
23.4742
Trailing PE
22.4551
PEG
-2.5

Its diluted EPS in the last 12-months stands at $1.67 per share while it has a forward price to earnings multiple of 23.4742 and a PEG multiple of -2.5. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Halozyme Therapeutics Inc’s profitability.

Halozyme Therapeutics Inc stock is trading at a EV to sales ratio of 15.7616 and a EV to EBITDA ratio of 31.4845. Its price to sales ratio in the trailing 12-months stood at 13.2809.

Halozyme Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$1.81 billion
Total Liabilities
$116.39 million
Operating Cash Flow
$54.99 million
Capital Expenditure
$1.62 million
Dividend Payout Ratio
0%

Halozyme Therapeutics Inc ended 2024 with $1.81 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $1.81 billion while shareholder equity stood at $151.03 million.

Halozyme Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $116.39 million in other current liabilities, 132000.00 in common stock, $140.45 million in retained earnings and $416.82 million in goodwill. Its cash balance stood at $221.17 million and cash and short-term investments were $348.28 million. The company’s total short-term debt was $0 while long-term debt stood at $1.50 billion.

Halozyme Therapeutics Inc’s total current assets stands at $765.75 million while long-term investments were $0 and short-term investments were $127.11 million. Its net receivables were $246.18 million compared to accounts payable of $10.12 million and inventory worth $132.41 million.

In 2024, Halozyme Therapeutics Inc's operating cash flow was $54.99 million while its capital expenditure stood at $1.62 million.

Comparatively, Halozyme Therapeutics Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$38.92
52-Week High
$59.46
52-Week Low
$29.85
Analyst Target Price
$51.8

Halozyme Therapeutics Inc stock is currently trading at $38.92 per share. It touched a 52-week high of $59.46 and a 52-week low of $59.46. Analysts tracking the stock have a 12-month average target price of $51.8.

Its 50-day moving average was $41.38 and 200-day moving average was $42.89 The short ratio stood at 6.29 indicating a short percent outstanding of 0%.

Around 98.5% of the company’s stock are held by insiders while 9656.2% are held by institutions.

Frequently Asked Questions About Halozyme Therapeutics Inc

The stock symbol (also called stock or share ticker) of Halozyme Therapeutics Inc is HALO

The IPO of Halozyme Therapeutics Inc took place on 2004-03-16

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$0.36
-0.01
-1.38%
$10.86
-0.04
-0.37%
$92.55
-4.85
-4.98%
$0
0
0%
$316.3
-21.65
-6.41%
$0.07
0
0%
$73.8
0.83
+1.14%
$19
-0.07
-0.37%
$1.6
0.03
+1.91%
Gujarat Gas Limited (GUJGASLTD)
$450.75
-9.45
-2.05%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company’s products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; XYOSTED, an injection for SC administration of testosterone replacement therapy; NOCDURNA, a sublingual tablet to treat nocturia due to nocturnal polyuria; TLANDO, an oral formulation for testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of multiple blood cancer; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergy and immunology; Sumatriptan injection for migraines; exenatide and teriparatide injections; Makena, a progestin drug to reduce the risk of preterm birth; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Address

11388 Sorrento Valley Road, San Diego, CA, United States, 92121